Search results for: 'industry 4.0\'

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision medicine. It highlights AI-driven platforms, advanced biologics, and digital health solutions that address critical challenges in accessibili...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides strategic insights into frontier innovations redefining therapeutic development, precision diagnostics, and immune modulating interventions. It showcases breakthroughs across engineered phage therapeutics, intracellular peptide platforms, advanced gene ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming respiratory medicine, liver regeneration, metabolic disease management, infectious disease therapeutics, neurological disorders, cardiovascular risk reduction, oncology workflows, and nex...

20 Nov 2017  |  North America  |  Market Research

Global Biologics Market—Companies-to-Action

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

Infographics

×

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the gro...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping diagnostics, therapeutics, and clinical workflows across infectious diseases, women’s health, metabolic disorders, neurodegeneration, oncology, rare diseases, and musculoskeletal care. It hi...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping therapeutics, diagnostics, and drug delivery across infectious diseases, oncology, rare genetic disorders, autoimmune conditions, cardiovascular disease, pulmonary fibrosis, neurodegeneratio...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and metabolic disorders, neuromuscular and neurodegenerative conditions, diabetes, ophthalmol...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming precision therapeutics, regenerative medicine, AI-enabled discovery, laboratory automation, targeted delivery, vaccines, and biomanufacturing across oncology, chronic disease, neurologica...